Soybean Extract Rich in Lunasin Enhances p21 Expression in DMBA-Induced Breast Cancer Rat: A Potential Adjuvant Therapy unasin enhances p21 in breast cancer
Abstract
Background: Breast cancer treatment in Indonesia faces challenges due to side effects, limited accessibility, and resistance to therapies like tamoxifen, highlighting the need for effective adjuvants strategies. Lunasin, a soybean-derived peptide, exhibits anticancer potential by upregulating p21, a tumor suppressor involved in cell cycle arrest and apoptosis. This study examines the effect of soybean extract rich in lunasin on p21 expression in a DMBA-induced breast cancer rat model.
Methods: Thirty female Sprague-Dawley rats were induced with breast cancer via intragastric injection of 7,12-Dimethylbenz[a]anthracene (DMBA), 20 mg/kgBW was given twice weekly for a total of 11 injections. Once the tumor volume reached 1-2 cm3, the rats were given 10 mg/kgBW of tamoxifen (positive control), 500 mg/kgBW of soybean extract rich in lunasin (lunasin), and a combination of both (combination) for eight weeks. Rats in the negative control group did not receive any medication. Afterwards, the rats were terminated to extract the tumor tissue. This tumor tissue was examined for the expression of p21 protein using immunohistochemistry staining.
Results: The highest average p21 expression was observed in the normal group, followed by combination, lunasin, positive control, and negative control groups. The combination group showed significantly higher p21 expression than negative control (p<0.05), while no significant difference was observed between the positive control and lunasin groups (p>0.05).
Conclusion: Soybean extract rich in lunasin upregulates p21, supporting its role in tumor suppression. While lunasin alone had no significant advantage over tamoxifen, their combination significantly increased p21 expression, suggesting a synergistic effect, making it a promising adjuvant therapy.
Full text article
References
Dattani S, Spooner F, Ritchie H, Roser M. Causes of death. Our World in Data. 2019.
International Agency for Research on Cancer. Global cancer observatory (GLOBOCAN). World Health Organization. 2022.
International Agency for Research on Cancer. Cancer today. World Health Organization. 2020.
Body of Research and Development. Basic Health Research 2013. Ministry of Health Republic of Indonesia. 2013.
Body of Research and Development. Basic Health Research 2018. Ministry of Health Republic of Indonesia. 2018.
Minister of Health Republic of Indonesia. National Guidelines for Medical Services in the Management of Breast Cancer. Ministry of Health Republic of Indonesia. 2018.
National Committee for Cancer Management. National Guidelines for Breast Cancer Management. Ministry of Health Republic of Indonesia. 2015.
Amjad MT, Chidharla A, Kasi A. Cancer chemotherapy. StatPearls. 2023.
Altun I, Sonkaya A. The most common side effects experience by patients were receiving first cycle of chemotherapy. Iran J Public Health. 2018;47(8):1218–9. PMID: 30186799
Rusdi NK, Yuliani WL, Purwaningsih EH, Hestiantoro A, Kusmardi K. Subchronic toxicity of lunasin targeted extract (ET-Lun) from soybean seed (Glycine max (L.) Merr.): perspective from liver histopathology, SGOT, and SGPT levels in sprague dawley rats. Pharmacogn J. 2021;13(6):1384–8. DOI: 10.5530/pj.2021.13.175
Hao Y, Guo H, Hong Y, Fan X, Su Y, Yang X, et al. Lunasin peptide promotes lysosome mitochondrial mediated apoptosis and mitotic termination in MDA-MB-231 cells. Food Science and Human Wellness. 2022;11(6):1589–606. DOI: https://doi.org/10.1016/j.fshw.2022.06.018
Bitar AS, Muhtasib HG. The role of the cyclin dependent kinase inhibitor p21/cip1/waf1 in targeting cancer molecular mechanisms and novel therapeutics. Cancers (Basel). 2019;11(10). DOI: 10.3390/cancers11101475
Rusdi NK. In vivo antimammary tumor effects of soybean extract with targeted lunasin (ET-Lun). Pharmarcognosy Journal. 2021;13(5):1269–76. DOI: 10.5530/pj.2021.13.160
Kusmardi K, Hermanto D, Estuningtyas A, Tedjo A, Priosoeryanto BP. The potency of Indonesia’s pomegranate peel ethanol extract (Punica Granatum Linn.) as anti-inflammatory agent in mice colon induced by dextran sodium sulfate: focus on cyclooxygenase-2 and INOS expressions. Asian Journal of Pharmaceutical and Clinical Research. 2017;10(12). DOI: https://doi.org/10.22159/ajpcr.2017.v10i12.21390
Kusmardi K, Wiyarta E, Estuningtyas A, Sahar N, Midoen YH, Tedjo A, et al. Potential inhibition by phaleria macrocarpa leaves ethanol extract on Ki-67 expression in distal colon mouse. Pharmacognosy Journal. 2021;13(2):443–9. DOI: 10.5530/pj.2021.13.56
Ayun NQ, Kusmardi, Nurhuda, Elya B. Anti-inflammation of soursop leaves (Annona muricata L.) against hemorrhoids in mice induced by croton oil. Pharmacognosy Journal. 2020;12(4):784–92. DOI: 10.5530/pj.2020.12.112
Jiao L, Wang S, Zheng Y, Wang N, Yang B, Wang D, et al. Betulinic acid suppresses breast cancer aerobic glycolysis via caveolin-1/NF-κB/c-Myc pathway. Biochem Pharmacol. 2019 Mar;161:149–62. DOI: 10.1016/j.bcp.2019.01.016
Nile SH, Nile A, Oh JW, Kai G. Soybean processing waste: Potential antioxidant, cytotoxic and enzyme inhibitory activities. Food Biosci. 2020;38. DOI: https://doi.org/10.1016/j.fbio.2020.100778
Farrar MC, Jacobs TF. Tamoxifen. StatPearls. 2023.
Zhuang T, Zhu J, Li Z, Lorent J, Zhao Chunyan, Wright KD, et al. p21-activated kinase group II small compound inhibitor GNE-2861 perturbs estrogen receptor alpha signaling and restores tamoxifen-sensitivity in breast cancer cells. Oncotarget. 2016;6:43853–68. DOI: 10.18632/oncotarget.6081
Kim CG, Choi BH, Son SW, Yi SJ, Shin SY, Lee YH. Tamoxifen-induced activation of p21Waf1/Cip1 gene transcription is mediated by Early Growth Response-1 protein through the JNK and p38 MAP kinase/Elk-1 cascades in MDA-MB-361 breast carcinoma cells. Cellular Signaling . 2007;19(6):1290–300. DOI: 10.1016/j.cellsig.2007.01.008
Yao J, Deng K, Huang J, Zeng R, Zuo J. Progress in the understanding of the mechanism of tamoxifen resistance in breast cancer. Front Pharmacol. 2020;11. DOI: 10.3389/fphar.2020.592912
Szymczyk AK, Kaczmarek W, Majewska KF, Gajewska KL. Lunasin and its epigenetic impact in cancer chemoprevention. Int J Mol Sci. 2023;24(11):9187. DOI: 10.3390/ijms24119187
Dia VP, de Meija E. Lunasin induces apoptosis and modifies the expression of genes associated with extracellular matrix and cell adhesion in human metastatic colon cancer cells. Mol Nutr Food Res. 2011;55(4):623–34. DOI: 10.1002/mnfr.201000419
Vuyyuri SB, Shidal C, Davis KR. Development of the plant-derived peptide lunasin as an anticancer agent. Curr Opin Pharmacol. 2018;41:27–33. DOI: 10.1016/j.coph.2018.04.006
Pang X, He X, Qiu Z, Zhang H, Xie R, Liu Z, et al. Targeting integrin pathways: mechanisms and advances in therapy. Signal Transduct Target Ther. 2023;8(1). DOI: https://doi.org/10.1038/s41392-022-01259-6
Tome SF, Xu F, Han Y, Ledesma BH, Xiao H. Inhibitory effects of peptide lunasin in colorectal cancer HCT-116 cells and their tumorsphere-derived subpopulation. Int J Mol Sci. 2020;21(2):537. DOI: 10.3390/ijms21020537
Shamloo B, Usluer S. p21 in cancer research. Cancers (Basel). 2019;11(8):1178. DOI: 10.3390/cancers11081178
Barr AR, Cooper S, Heldt FS, Butera F, Stoy H, Mansfeld J, et al. DNA damage during S-phase mediates the proliferation-quiescence decision in the subsequent G1 via p21 expression. Nat Commun. 2017;8. DOI: https://doi.org/10.1038/ncomms14728
Engeland K. Cell cycle regulation: p53-p21-RB signaling. Cell Death Differ. 2022;29:946–60. DOI: https://doi.org/10.1038/ncomms14728
Jain MV, Jangamreddy JR, Grabarek J, Schweizer F, Klonisch T, Pobuda AC, et al. Nuclear localized Akt enhances breast cancer stem-like cells through counter-regulation of p21Waf1/Cip1 and p27kip1. Cell Cyle. 2015;14(13):2109–20. DOI: 10.1080/15384101.2015.1041692
Hsieh CC, Wu CH, Peng SH, Chang CS. Seed-derived peptide lunasin suppressed breast cancer cell growth by regulating inflammatory mediators, aromatase, and estrogen receptors. Food Nutr Res. 2023 Jan 6;67. DOI: 10.29219/fnr.v67.8991
Jiang Q, Pan Y, Cheng Y, Li H, Liu D, Li H. Lunasin suppresses the migration and invasion of breast cancer cells by inhibiting matrix metalloproteinase-2/-9 via the FAK/Akt/ERK and NF-κB signaling pathways. Oncol Rep. 2016;36(1):253–62. DOI: 10.3892/or.2016.4798
Barde MP, Barde PJ. What to use to express the variability of data: Standard deviation or standard error of mean? Perspect Clin Res. 2012;3(3):113–6. DOI: 10.4103/2229-3485.100662
Wang X, Liu H, Sung Y, Zhang J, Chen Xi, Chen N. Lunasin: a promising polypeptide for the prevention and treatment of cancer. Oncol Lett. 2017;13(6):3997–4001. DOI: 10.3892/ol.2017.6017
Jones G, Srivastava A. Understanding lunasin’s biology and potential as a cancer therapeutic by utilizing drosophila genetics. Exp Biol Med. 2014;239(5). DOI: 10.1177/1535370214522180. DOI: 10.1177/1535370214522180
Hsieh CC, Villaluenga CM, de Lumen BO, Ledesma BH. Updating the research on the chemopreventive and therapeutic role of the peptide lunasin. J Sci Food Agric. 2018;98(6):2070–9. DOI: 10.1002/jsfa.8719
Diao L, Meibohm B. Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides. Clin Pharmacokinet. 2013;52(10):855–68. DOI: 10.1007/s40262-013-0079-0
Tomé SF, Sanchón J, Recio I, Ledesma BH. Transepithelial transport of lunasin and derived peptides: Inhibitory effects on the gastrointestinal cancer cells viability. J Food Comp Anal. 2018;68:101–10. DOI: 10.3390/ijms21020537
Hsieh CC, Ledesma BH, Jeong HJ, Park JH, de Lumen BO. Complementary roles in cancer prevention: protease inhibitor makes the cancer preventive peptide lunasin bioavailable. PLoS One. 2010;5(1):e8890. DOI: 10.1371/journal.pone.0008890
Souza SMA de, Ledesma BH, Souza TLF de. Lunasin as a promising plant-derived peptide for cancer therapy. Int J Mol Sci. 2022 Sep;23(17):9548. DOI: 10.3390/ijms23179548
Shidal C, Al-Rayyan N, Yaddanapudi K, Davis KR. Lunasin is a novel therapeutic agent for targeting melanoma cancer stem cells. Oncotarget. 2016;7(51):84128–41. DOI: 10.18632/oncotarget.11554
Dzirkale Z, Nakurte I, Jekabsons K, Muceniece R, Klusa V. Intra-nasally administered oligopeptide lunasin acts as a possible anti-psychotic agent in mice models. Medicina (Kaunas). 2019;55(7):393. DOI: 10.3390/medicina55070393
Authors
Copyright (c) 2025 Archives of Breast Cancer
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright©. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International License, which permits copy and redistribution of the material in any medium or format or adapt, remix, transform, and build upon the material for any purpose, except for commercial purposes.